Heartland Advisors’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

Heartland Advisors’s Portfolio EVFM Stock Details EVFM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-73,333	Closed	-$1.24M	–	225
2021 Q2	$1.24M	Sell	73,333 -103,694	-59%	-$1.97M	0.07%	215
2021 Q1	$4.65M	Buy	177,027 +5,567	+3%	+$253K	0.29%	139
2020 Q4	$6.2M	Buy	171,460 +16,817	+11%	+$608K	0.44%	94
2020 Q3	$5.47M	Buy	154,643 +54,643	+55%	+$2.38M	0.48%	95
2020 Q2	$4.25M	Buy	100,000 +40,000	+67%	+$2.7M	0.38%	111
2020 Q1	$4.79M	Hold	60,000	–	–	0.51%	90
2019 Q4	$5.55M	Hold	60,000	–	–	0.41%	112
2019 Q3	$4.54M	Buy	60,000 +3,333	+6%	+$256K	0.35%	123
2019 Q2	$5.64M	Buy	56,667 +1,667	+3%	+$129K	0.42%	110
2019 Q1	$2.89M	Buy	55,000 +3,447	+7%	+$187K	0.21%	149
2018 Q4	$3.24M	Buy	51,553 +29,848	+138%	+$1.64M	0.27%	134
2018 Q3	$1.32M	Buy	+21,705	New	+$940K	0.09%	171

Other funds holding EVFM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

FWSM

First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Heartland Advisors's EVFM Position: Q3 2021 in Review

Heartland Advisors sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q3 2021, closing a stake of 73,333 shares — an estimated $1.24M sold.

Heartland Advisors first reported a position in EVFM in Q3 2018 and held it in 12 quarters. The position peaked at $6.2M in Q4 2020. 71 funds tracked by Wall St. Rank hold EVFM as of Q3 2021.

Heartland Advisors reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
Heartland Advisors sold 73,333 Evofem Biosciences, Inc. Common Stock shares in Q3 2021, an estimated $1.24M.
Heartland Advisors first reported a position in Evofem Biosciences, Inc. Common Stock in Q3 2018 and held it in 12 quarters.
Heartland Advisors's Evofem Biosciences, Inc. Common Stock position peaked at $6.2M in Q4 2020.
71 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q3 2021.

Based on Heartland Advisors's 13F filing for Q3 2021, filed 9 Nov 2021.